MedTrace Logo

The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors

NCT01317147 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2011-03-17

No results posted yet for this study

Summary

The morbidly obese frequently present with mood and anxiety disorders, which are often treated with serotonin reuptake inhibitors (SRI) antidepressant drugs. The investigators hypothesized that gastric bypass surgery would decrease the absorption of SRI. The investigators also wished to determine whether a reduction in SRI levels would increase the likelihood of worsening depressive symptoms.

Conditions

Interventions

PROCEDURE

Roux-en-Y gastric bypass (RYGBP)

Sponsors & Collaborators

  • American Society for Metabolic and Bariatric Surgery

    collaborator OTHER

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Giselle Hamad, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317147 on ClinicalTrials.gov